{"protocolSection":{"identificationModule":{"nctId":"NCT06470542","orgStudyIdInfo":{"id":"9/2024"},"organization":{"fullName":"Poznan University of Medical Sciences","class":"OTHER"},"briefTitle":"Two-level ESPB in Total Knee Arthroplasty","officialTitle":"Two-level vs One-level Erector Spinae Plane Block in Total Knee Arthroplasty"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09-30","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-09-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-10-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-17","studyFirstSubmitQcDate":"2024-06-17","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-17","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Poznan University of Medical Sciences","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Effect of two-level ESPB in Total Knee Arthroplasty","detailedDescription":"Knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects."},"conditionsModule":{"conditions":["Knee Osteoarthritis","Knee Pain Chronic","Knee Arthritis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"One-level ESPB","type":"ACTIVE_COMPARATOR","description":"Ultrasound-guided ESPB at the L2 level","interventionNames":["Drug: 20 ml of Ropivacaine 0.2% Injectable Solution"]},{"label":"Two-Level ESPB","type":"ACTIVE_COMPARATOR","description":"Bi-level Ultrasound-guided ESPB et the L1 and L4 level","interventionNames":["Drug: 2 x 20ml of Ropivacaine 0.2% Injectable Solution"]}],"interventions":[{"type":"DRUG","name":"20 ml of Ropivacaine 0.2% Injectable Solution","description":"20ml 0.2% Ropivacaine - ultrasound-guided ESPB at the L2 level","armGroupLabels":["One-level ESPB"],"otherNames":["Erector spinae plane block (ESPB)"]},{"type":"DRUG","name":"2 x 20ml of Ropivacaine 0.2% Injectable Solution","description":"2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and L4 level","armGroupLabels":["Two-Level ESPB"],"otherNames":["Erector spinae plane block (ESPB)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Total Opioid Consumption","description":"Total opioid consumption after surgery - within 48 hours after surgery","timeFrame":"48 hours after surgery"}],"secondaryOutcomes":[{"measure":"Time to first rescue opioid analgesia","description":"Time after surgery when the patient needs opiate for the first time","timeFrame":"48 hours after surgery"},{"measure":"Numerical Rating Scale [range 0:10]","description":"Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)","timeFrame":"8 hours after surgery"},{"measure":"Numerical Rating Scale [range 0:10]","description":"Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)","timeFrame":"12 hours after surgery"},{"measure":"Numerical Rating Scale [range 0:10]","description":"Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)","timeFrame":"24 hours after surgery"},{"measure":"Numerical Rating Scale [range 0:10]","description":"Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)","timeFrame":"48 hours after surgery"},{"measure":"NLR","description":"neutrophil-to-lymphocyte ratio","timeFrame":"24 hours after surgery"},{"measure":"NLR","description":"neutrophil-to-lymphocyte ratio","timeFrame":"48 hours after surgery"},{"measure":"PLR","description":"platelet-to-lymphocyte ratio","timeFrame":"24 hours after surgery"},{"measure":"PLR","description":"platelet-to-lymphocyte ratio","timeFrame":"48 hours after surgery"},{"measure":"Quadriceps muscle strength assessed using medical research council scale [range 0:5]","description":"Quadriceps muscle strength (knee extension and hip adduction) will be evaluated according to the medical research council muscle strength rating","timeFrame":"4 hours after surgery"},{"measure":"Quadriceps muscle strength assessed using medical research council scale [range 0:5]","description":"Quadriceps muscle strength (knee extension and hip adduction) will be evaluated according to the medical research council muscle strength rating","timeFrame":"8 hours after surgery"},{"measure":"Quadriceps muscle strength assessed using medical research council scale [range 0:5]","description":"Quadriceps muscle strength (knee extension and hip adduction) will be evaluated according to the medical research council muscle strength rating","timeFrame":"12 hours after surgery"},{"measure":"Quadriceps muscle strength assessed using medical research council scale [range 0:5]","description":"Quadriceps muscle strength (knee extension and hip adduction) will be evaluated according to the medical research council muscle strength rating","timeFrame":"24 hours after surgery"},{"measure":"Quadriceps muscle strength assessed using medical research council scale [range 0:5]","description":"Quadriceps muscle strength (knee extension and hip adduction) will be evaluated according to the medical research council muscle strength rating","timeFrame":"48 hours after surgery"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients scheduled for total hip arthroplasty\n* patients aged \\>65 and \\<100 years\n* patients able to provide informed consent\n* patients able to reliably report symptoms to the research team\n\nExclusion Criteria:\n\n* inability to provide first-party consent due to cognitive impairment or a language barrier","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","maximumAge":"100 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Malgorzata Domagalska, M.D. Ph.D.","role":"CONTACT","phone":"(61) 873-83-03","email":"mdomagalska@ump.edu.pl"}],"overallOfficials":[{"name":"Malgorzata Domagalska, M.D. Ph.D.","affiliation":"PoznaÅ„ University of Medical Sciences","role":"STUDY_CHAIR"}],"locations":[{"facility":"Poznan University of Medical Sciences","city":"Poznan","state":"PoznaÅ„","zip":"61-701","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Detailed data sharing plan to be defined","timeFrame":"Data will be shared following the trial completion","accessCriteria":"Eligible researchers"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000010003","term":"Osteoarthritis"},{"id":"D000020370","term":"Osteoarthritis, Knee"}],"ancestors":[{"id":"D000001168","term":"Arthritis"},{"id":"D000007592","term":"Joint Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000012216","term":"Rheumatic Diseases"}],"browseLeaves":[{"id":"M12926","name":"Osteoarthritis","asFound":"Osteoarthritis","relevance":"HIGH"},{"id":"M22168","name":"Osteoarthritis, Knee","asFound":"Knee Osteoarthritis","relevance":"HIGH"},{"id":"M13066","name":"Pain","relevance":"LOW"},{"id":"M4476","name":"Arthritis","relevance":"LOW"},{"id":"M10621","name":"Joint Diseases","relevance":"LOW"},{"id":"M12097","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M15045","name":"Rheumatic Diseases","relevance":"LOW"},{"id":"M6323","name":"Collagen Diseases","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077212","term":"Ropivacaine"},{"id":"D000019999","term":"Pharmaceutical Solutions"}],"ancestors":[{"id":"D000000779","term":"Anesthetics, Local"},{"id":"D000000777","term":"Anesthetics"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M21860","name":"Pharmaceutical Solutions","asFound":"Procedure","relevance":"HIGH"},{"id":"M1700","name":"Ropivacaine","asFound":"Eye","relevance":"HIGH"},{"id":"M4107","name":"Anesthetics","relevance":"LOW"},{"id":"M4109","name":"Anesthetics, Local","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"}]}},"hasResults":false}